Zusammenfassung
In der Bundesrepublik Deutschland verstarben im Jahr 2002 knapp 70.000 Menschen aufgrund eines akuten Myokardinfarkts (AMI), etwa 37% verstarben noch vor Erreichen der Klinik. Dies unterstreicht die besondere Relevanz einer adäquaten prähospitalen Versorgung. Anlass für die Einführung des gemeinsamen Oberbegriffes akutes Koronarsyndrom (ACS) ist der gemeinsame Pathomechanismus der verschiedenen ACS-Formen. Die Definition reicht von der instabilen Angina pectoris (iAP) über den Nicht-ST-Streckenhebungsinfarkt (NSTEMI) und den ST-Streckenhebungsinfarkt (STEMI) bis zum plötzlichen Herztod (PHT). Charakteristisch sind retrosternale Schmerzen, ggf. eine vegetative Symptomatik und Ausstrahlung des Schmerzes. Weiter differenziert wird das ACS nur durch das 12-Kanal EKG; herzspezifische Enzyme haben prähospital therapeutisch zurzeit keinen Stellenwert. Anamnese und Untersuchung sollten kurz und gezielt erfolgen, die Vitalparameter des Patienten engmaschig überwacht werden. Die Basistherapie besteht aus inhalativer Sauerstoffgabe, sublingualer Gabe von Glyceroltrinitrat, Morphin, Acetylsalicylsäure (ASS) und ggf. β-Blockern über einen peripher-venösen Zugang. Lässt sich die Diagnose STEMI durch 12-Kanal EKG und Anamnese eindeutig stellen, sollte bei allen Patienten ohne Kontraindikationen mit einer Fibrinolyse begonnen werden, sofern zu erwarten ist, dass die Verzögerung bis zu einer perkutanen koronaren (Katheter-)Intervention (PCI) >90 min und die Symptomdauer weniger als 12 h beträgt. Besonders günstig ist eine Symptomdauer <3 h. Patienten mit STEMI erhalten Heparin in Abhängigkeit von dem verwendeten Fibrinolytikum, eine Routinegabe von Heparin erhöht bei diesen Patienten die Blutungsrate, während Heparin bei Patienten mit iAP oder NSTEMI insgesamt das weitere Risiko senkt. Alle ACS-Patienten müssen vom Notarzt ins Krankenhaus begleitet werden. Patienten mit Komplikationen bzw. Kontraindikationen für eine Fibrinolyse sollten nach Möglichkeit in ein Zentrum mit akut verfügbarer Interventionsmöglichkeit (PCI) gebracht werden. Patienten mit unkompliziertem ACS können in jede Klinik mit einer geeigneten Intensivstation gebracht werden. Die Behandlung von Begleitkomplikationen richtet sich nach der Art und dem klinischem Schweregrad der Störung.
Abstract
Cardiovascular diseases are the number one cause of death in Germany. In 2002 about 70,000 people died of acute myocardial infarction (AMI) and of these 37% died before arrival at hospital which underlines the relevance of adequate prehospital care. The generic term acute coronary syndrome (ACS) was introduced because a single pathomechanism accounts for the different forms and comprises unstable angina pectoris (iAP), non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI) and sudden cardiac death (SCD). Characteristic features are retrosternal pain, vegetative symptoms and radiation of pain into the adjoining regions. Further differentiation can only be achieved by the 12-lead ECG, as cardiac-specific enzymes do not play a role in prehospital decisions. Prehospital delays should be avoided, history and physical examination should be brief but focused, vital parameters should be assessed and monitored. Basic treatment for ACS should comprise inhalative oxygen, nitrates, morphine, aspirin and β-blockers. If STEMI is diagnosed, patients with symptoms <12 h should undergo fibrinolytic therapy unless there is primary percutaneous coronary intervention (PCI) available within 90 min or if contraindicated. Heparin should be given to patients with STEMI depending on the choice of fibrinolytic agent, it otherwise results in a higher risk of bleeding, but in patients with iAP or NSTEMI it reduces mortality. All patients must be accompanied by the emergency physician during transportation and should be brought to a hospital with primary PCI, especially those with complicated ACS. Treatment of complications depends largely on the type, persistence and severity.
Literatur
Akkerhuis KM, Klootwijk PA, Lindeboom W, Umans VA, Meij S, Kint P, Simoons ML (2001) Recurrent ischaemia during continuous multilead St-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients. Eur Heart J 22:1997–2006
Ambrosioni E, Borghi C, Magnani B (1995) The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction: the Survival of Myocardial Infarction: Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 332:80–85
Antman EM (2002) Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 360:1189–1196
Antman EM, Berlin JA (1992) Declining incidence of ventricular fibrillation in myocardial infarction. Implications for the prophylactic use of lidocaine. Circulation 86:764–773
Antman EM, McCabe CH, Gurfinkel EP et al. (1999) Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 100:1593–1601
Antman EM, Cohen M, Radley D et al. (1999) Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE metaanalysis. Circulation 100:1602–1608
Antman EM, Anbe DT, Armstrong PW et al. (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Circulation 110:588–636
Antiplatelet Trialists‘ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81–106
Antithrombotic Trialists‘ Collaboration (2002) Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86
Arntz HR, Stern R, Linderer T (1992) Efficiency of a physician-operated mobile intensive care unit for prehospital thrombolysis in acute myocardial infarction. Am J Cardiol 80:417–420
Arntz HR, Tebbe U, Schuster HP, Sauer G, Meyer J (2000) Leitlinien zur Diagnostik und Therapie des akuten Herzinfarkts in der Prähospitalphase. Z Kardiol 89:364–370
Aronow WS (1998) Use of beta-bockers during and after myocardial infarction. Comp Ther 24:327–331
ASSENT-2: Assessment of the Safety and Efficacy of a New Thrombolytic Investigators (1999) Singlebolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 354:716–722
Aufderheide TP, Kereiakes DJ, Weaver WD, Gibler WB, Simoons ML (1996) Planning, implementation and process monitoring for prehospital 12-lead ECG diagnostic programs. Prehospital Disaster Med 11:162–171
Bertrand ME, Simoons ML, Fox KAA et al. (2002) Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 23:1809–1840
Bippus PH, Storch WH, Andresen D, Schröder R (1987) Thrombolysis started at home in acute myocardial infarction: feasibility and time-gain. Circulation 76:122
Bode WE (1992) Non-Q-wave myocardial infarction: a prognostic paradox. Hosp Pract 27:79–92
Boersma E, Maas A, Deckers J, Simons M (1996) Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 348:771–775
Bonnefoy E, Lapostolle F, Leizorovicz A et al. (2002) Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) Study Group. Lancet 360:825–829
Böttiger BW, Grabner C, Bauer H, Bode C, Weber T, Motsch J, Martin E (1999) Long term outcome after out-of-hospital cardiac arrest with physician staffed emergency medical services: the Utstein style applied to a midsized urban/suburban area. Heart 82:674–679
Böttiger BW, Bode C, Kern S et al. (2000) Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. Lancet 357:1583–1585
Braunwald E, Antman EM, Beasley JW et al. (2002) American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction — 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 106:1893–1900
Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ (1998) Heparin-induced thrombocytopenia. J Am Coll Cardiol 31:1449–1459
Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R (1997) Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 336:1276–1282
Cairns JA, Singer J, Gent M et al. (1989) One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000 people. Can J Cardiol 5:239–246
Cannon CP, Gibson CM, McCabe CH et al. (1998) TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 98:2805–2814
Canto JG, Every NR, Magid DJ et al. (2000) The volume of primary angioplasty procedures and survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. N Engl J Med 342:1573–1580
CAPTURE Investigators (1997) Randomised placebo-controlled trial of abciximab before and during intervention in refractory unstable angina: the CAPTURE study. Lancet 349:1429–1435
Casale PN, Jones JL, Wolf FE, Pei Y, Eby LM (1998) Patients treated by cardiologists have a lower in-hospital mortality for acute myocardial infarction. J Am Coll Cardiol 32:885–889
Castaigne AD, Herve C, Duval-Moulin AM et al. (1989) Prehospital use of APSAC: results of a placebo-controlled study. Am J Cardiol 64:30A–33A
CCS-1 (1995) Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study. Lancet 345:686–687
Chambless L, Keil U, Dobson A et al. (1997) Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985–1990. Multinational Monitoring of Trends and Determinants in Cardiovascular Disease. Circulation 96:3849–3859
Cohen MC, Rohtla KM, Lavery CE, Muller JE, Mittleman MA (1997) Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 79:1512–1516
Cohen M, Demers C, Gurfinkel EP et al. (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 337:447–452
Colquhoun MC, Julien DG (1992) Sudden death in the community: the arrhythmia causing cardiac arrest and results of immediate resuscitation. Resuscitation 24:177A
Dahlback B (2000) Blood coagulation. Lancet 355:1627–1632
Dalby M, Bouzamondo A, Lechat P, Montalescot G (2003) Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation 108:1809–1814
Davies MJ (2000) The pathophysiology of acute coronary syndromes. Heart 83:361–366
Dracup K, Alonzo AA, Atkins JM et al. (1997) The physician’s role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program. Working Group on Educational Strategies to Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction. Ann Intern Med 126:645–651
Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S (2000) Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 355:1936–1942
El-Sherif N, Myerburg RJ, Scherlag BJ, Befeler B, Aranda JM, Castellanos A, Lazzara R (1976) Electrocardiographic antecedents of primary ventricular fibrillation: value of the R-on-T phenomenon in myocardial infarction. Br Heart J 38:415–422
European Myocardial Infarction Project Group (1993) (EMIP) Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 329:383–389
Falk E (1985) Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 71:699–708
Farb A, Tang AL, Burke AP, Sessums L, Liang Y, Virmani R (1995) Sudden coronary death: frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation 92:1701–1709
Fibrinolytic Trialists Collaborative Group (FTT) (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343:311–322
Fresco C, Franzosi MG, Maggioni AP, Tognoni G (1990) The GISSI-2 trial: premises, results, epidemiological (and other) implications Gruppo Italiano per lo Studio delia Sopravvivenza nell’Infarto Miocardico. Clin Cardiol 13:32–36
FRISC study group (1996) Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 347:561–568
Furberg CD, Psaty BM, Mayer JV (1995) Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 92:1326–1331
Garber PJ, Gu S, Ducas J, Schick U, Prewitt RM (1995) An increase in low aortic pressure increases coronary artery flow and coronary thrombolysis induced by intravenous administration of recombinant tissue plasminogen activator. J Crit Care 10:1–6
Gillum RF, Fortmann SP, Prineas RJ, Kottke TE (1984) International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J 108:150–158
GISSI-Avoidable Delay Study Group (1995) Epidemiology of avoidable delay in the care of patients with acute myocardial infarction in Italy. A GISSI-generated study. Arch Intern Med 155:1481–1488
GISSI-3 (1994) Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction: Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet 343:1115–1122
GREAT Group (1992) Feasibility, safety and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. BMJ 305:548–553
Grijseels EW, Deckers JW, Hoes AW, Hartman JA, Does E van der, Loenen E van, Simoons ML (1995) Pre-hospital triage of patients with suspected myocardial infarction. Evaluation of previously developed algorithms and new proposals. Eur Heart J 16:325–332
Gust R, Gust A, Böttiger BW, Böhrer H, Martin E (1998) Bedside troponin T testing is not useful for early out-of-hospital diagnosis of myocardial infarction. Acta Anesthesiol Scand 42:414–417
GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682
GUSTO III: The Global Use of Strategies to Open Occluded Coronary Arteries Investigators (1997) A comparsion of reteplase with alteplase for acute myocardial infarction. N Engl J Med 337:1118–1123
Hamm CW, Bertrand M, Braunwald E (2001) Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet 358:1533–1538
Hamm CW, Arntz HR, Bode C et al. (2004) Leitlinien. Akutes Koronarsyndrom. Teil 1: ACS ohne persistierende ST-Hebung. Z Kardiol 93:72–90
Hamm CW, Arntz HR, Bode C et al. (2004) Leitlinien. Akutes Koronarsyndrom. Teil 2: ACS mit persistierender ST-Hebung. Z Kardiol 93:324–341
Hochman JS, Sleeper LA, Webb JG et al. (1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 341:625–634
Hochman JS, Sleeper LA, White HD et al. (2001) One-year survival following early revascularization for cardiogenic shock. JAMA 285:190–192
Holmvang L, Andersen K, Dellborg AK et al. (1999) Relative contributions of a single-admission 12-lead electrocardiogram and early 24-hour continuous electrocardiographic monitoring for early risk stratification in patients with unstable coronary artery disease. Am J Cardiol 83:667–674
ISIS-1 (1988) Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Lancet 1:921–923
ISIS-2 (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2:349–360
ISIS-3 (Third International Study on Infarct Survival) Collaborative Group (1992) A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreptase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 339:753–770
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group (1994) ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345:669–685
Joint European Society of Cardiology/American College of Cardiology Commitee (2000) Myocardial infarction redefined — A consensus document of the Joint European Society of Cardiology/American College of Cardiology for the redefinition of myocardial infarction. Eur Heart J 21:1502–1513
Joint International Society and Federation of Cardiology/World Health Organization Task Force on standardization of clinical nomenclature (1979) Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 59:607–609
Jugdutt BI, Warnica JW (1988) Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications: effect of timing, dosage, and infarct location. Circulation 78:906–919
Juliard JM, Himbert D, Cristofini P et al. (1999) A matched comparison of the combination of rehospital thrombolysis and standby rescue angioplasty with primary angioplasty. Am J Cardiol 83:305–310
Karagounis L, Ipsen SK, Jessop MR et al. (1990) Impact of field-transmitted electrocardiography on time to in-hospital thrombolytic therapy in acute myocardial infarction. Am J Cardiol 66:786–791
Kharb S, Singh V (2000) Magnesium deficiency potentiates free radical production associated with myocardial infarction. J Assoc Physicians India 48:484–485
Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361:13–20
Kereiakes DJ, Gibler WB, Martin LH, Pieper KS, Anderson LC (1992) Relative importance of emergency medical system transport and the prehospital electrocardiogram on reducing hospital time delay to therapy for acute myocardial infarction: a preliminary report from the Cincinnati Heart Project. Am Heart J 123:835–840
Koenig W (1998) Epidemiology of coronary heart disease. Z Kardiol 87:3–7
Kudenchuk PJ, Ho MT, Weaver WD et al. (1991) Accuracy of computer-interpreted electrocardiography in selecting patients for thrombolytic therapy. MITI Project Investigators. J Am Coll Cardiol 17:1486–1491
Larsson H, Areskog M, Areskog NH, Jonasson T, Ringqvist I, Fellenius C, Wallentin L (1995) The diagnostic and prognostic importance of ambulatory ST recording compared to a predischarge exercise test after an episode of unstable angina or non-Q wave myocardial infarction. Eur Heart J 16:888–893
Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G (1995) ACE-inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation 92:3132–3137
Latorre F de, Nolan J, Robertson C, Chamberlain D, Baskett P (2001) European Resuscitation Council Guidelines 2000 for Adult Advanced Life Support. Resuscitation 48:211–221
Lederer W, Lichtenberger C, Pechlaner C, Kroesen G, Baubin M (2001) Recombinant tissue plasminogen activator during cardiopulmonary resuscitation in 108 patients with out-of-hospital cardiac arrest. Resuscitation 50:71–76
Leizorovicz A, Haugh MC, Mercier C, Boissel JP on behalf of the EMIP Group (1997) Pre-hospital and hospital. Lancet 343:311–322
Libby P (2001) Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104:365–372
Lie KI, Wellens HJ, Downar E, Durrer D (1975) Observations on patients with primary ventricular fibrillation complicating acute myocardial infarction. Circulation 52:755–759
Löwel H, Engel S, Hörmann A, Gostomzyk J, Bolte HD, Keil U für das MONICA-Augsburg Herzinfarktregisterteam (1999) Notfallmedizin: Akuter Herzinfarkt und plötzlicher Herztod aus epidemiologischer Sicht. Intensivmedizin 36:652–661
Longstreth WT Jr, Litwin PE, Weaver WD (1993) Myocardial infarction, thrombolytic therapy, and stroke. A community-based study. The MITI Project Group. Stroke 24:587–590
Loubeyre C, Lefevre T, Louvard Y et al. (2001) Outcome after combined reperfusion therapy for acute myocardial infarction, combining pre-hospital thrombolysis with immediate percutaneous coronary intervention and stent. Eur Heart J 22:1128–1135
Luiz T, Ellinger K, Budde A, Hechler C, Klar H, Riester T (1998) Evaluierung eines qualitativen Schnelltestes für kardiales Troponin T zur präklinischen Diagnostik bei Patienten mit akutem Koronarsyndrom. Z Kardiol 4:267–275
Madias JE, Madias NE, Hood WB Jr (1976) Precordial ST-segment mapping, II: effects of oxygen inhalation on ischemic injury in patients with acute myocardial infarction. Circulation 53:411–417
Maroko PR, Radvany P, Braunwald E, Hale SL (1975) Reduction of infarct size by oxygen inhalation following acute coronary occlusion. Circulation 52:360–368
Matsusaka T, Hasebe N, Jin YT, Kawabe J, Kikuchi K (2002) Magnesium reduces myocardial infarct size via enhancement of adenosine mechanism in rabbits. Cardiovasc Res 54:568–575
Merkhof LF van den, Zijlstra F, Olsson H et al. (1999) Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) Pilot Study. J Am Coll Cardiol 33:1528–1532
MIAMI Trial Research Group (1985) Metoprolol in acute myocardial infarction: patient population. Am J Cardiol 56:1G–57G
Montalescot G, Barragan P, Wittenberg O et al. (2001) Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344:1895–1903
Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ (2000) Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 283:2686–2692
Morrow DA, Antman EM, Sayah A et al. (2002) Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 Trial. J Am Coll Cardiol 40:71–77
Nallamothu B, Bates ER (2003) Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 92:824–826
National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee (1995) Staffing and equipping emergency medical services system: rapid identification and treatment of acute myocardial infarction. Am J Emerg Med 13:58–66
National Heart Attack Alert Program Coordinating Committee (1998) Access to timely and optimal care of patients with acute coronary syndromes — Community planning considerations: a report by the National Heart Attack Alert Program. J Thromb Thrombolysis 6:19–47
Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U (1989) Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 14:1566–1569
Newman DH, Greenwald I, Callaway CW (2000) Cardiac arrest and the role of thrombolytic agents. Ann Emerg Med 35:472–480
Norris RM (1998) Fatality outside hospital from acute coronary events in three British districts, 1994–5. United Kingdom Heart Attack Study Collaborative Group. BMJ 316:1065–1070
O’Doherty M, Taylor DI, Quinn E, Vincent R, Chamberlain DA (1983) Five hundred patients with myocardial infarction monitored within one hour of symptoms. BMJ 286:1405–1408
Oler A, Whooley MA, Oler J, Grady D (1996) Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 276:811–815
Pantridge JF, Geddes JS (1967) A mobile intensive-care unit in the management of myocardial infarction. Lancet 2:271–273
PARAGON Investigators (1998) International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 97:2386–2395
Patel DJ, Holdright DR, Knight CJ et al. (1996) Early continuous ST segment monitoring in unstable angina: prognostic value additional to the clinical characteristics and the admission electrocardiogram. Heart 75:222–228
Popma JJ, Califf RM, Ellis SG et al. (1992) Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study. J Am Coll Cardiol 20:1305–1312
Popovic AD, Neskovic AN, Babic R et al. (1994) Independent impact of thrombolytic therapy and vessel patency on left ventricular dilation after myocardial infarction. Serial echocardiographic follow-up. Circulation 90:800–807
PRISM Investigators (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 338:1498–1505
PRISM-PLUS Investigators (1998) Inhibition of the platelet glycoprotein IIb/IIIa with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338:1488–1497
PURSUIT Investigators (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 339:436–443
Rao AK, Pratt C, Berke A et al. (1988) Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1–11
Rat der Europäischen Gemeinschaften (1991) Entscheidung des Rates vom 29. Juli 1991 zur Einführung einer einheitlichen europäischen Notrufnummer (91/396/EWG). Amtsblatt der Europäischen Gemeinschaften L 217/31 (6–8-91)
Rawles J (1994) Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 23:1–5
Rawles J (2003) GREAT: 10 year survival of patients with suspected acute myocardial infarction in a randomised comparison of prehospital and hospital thrombolysis. Heart 89:563–564
Reimer KA, Lowe JE, Rasmussen MM, Jennings RB (1977) The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 56:786–794
RISC Group (1990) Risc of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336:827–830
Robertson C, Stehen P, Adgey J et al. (1998) The 1998 European Resuscitation Council guidelines for adult advanced life support. Resuscitation 37:81–90
Rosenberg RD, Aird WC (1999) Vascular-bed: specific hemostasis and hypercoagulable states. N Engl J Med 340:1555–1564
Ross AM, Coyne KS, Reiner JS et al. (1999) A randomized trial comparing primary angioplasty with a strategy of short acting thrombolysis and immediate planned rescue angiolasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol 34:1954–1962
Sabatine MS, McCabe CH, Gibson CM, Cannon CP (2005) Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. Am Heart J 149:227–233
Savonitto S, Ardissino D, Granger CB et al. (1999) Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 281:707–713
Shechter M, Hod H, Chouraqui P, Kaplinsky E, Rabinowitz B (1995) Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolytic therapy. Am J Cardiol 75:321–323
Schofer J, Buttner J, Geng G et al. (1990) Prehospital thrombolysis in acute myocardial infarction. Am J Cardiol 66:1429–1433
Scholz KH, Tebbe U, Hermann G, Woijcik J, Lingen JM, Chemnitius JM (1992) Frequency of complications of cardiopulmonary resuscitation after thrombolysis during acute myocardial infarction. Am J Cardiol 69:724–728
Schuchert A, Hamm C, Scholz J, Klimmeck S, Goldmann B, Meinertz T (1999) Prehospital testing for troponin T in patients with suspected acute myocardial infarction. Am Heart J 138:45–48
Simoons ML, Maggioni AP, Knatterud G et al. (1993) Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 342:1523–1528
Sigurdsson A, Swedberg K (1994) Left ventricular remodelling, neurohormonal activation and early treatment with enalapril (CONSENSUS II) following myocardial infarction. Eur Heart J 15:14–19
Silfvast T (1991) Cause of death in unsuccessful prehospital resuscitation. J Intern Med 229:331–335
Spaulding CM, Joly LM, Rosenberg A, Monchi M, Weber SN, Dhainaut JF, Carli P (1997) Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med 336:1629–1633
Steg PG, Bonnefoy E, Chaubaud S et al. (2003) Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty. Circulation 108:2851–2856
Statistisches Bundesamt (2002) Gesundheitswesen: Todesursachen in Deutschland. Fachserie 12/ Reihe 4
Task Force Report (1998) The pre-hospital management of acute heart attacks. Eur Heart J 19:1140–1164
Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology (1996) Acute myocardial infarction: pre-hospital and in-hospital management. Eur Heart J 17:43–63
Theroux P, Waters D, Qiu S, McCans J, Guise P de, Juneau M (1993) Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 88:2045–2048
TIMI Study Group (1989) Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 320:618–627
Thiemann DR, Coresh J, Schulman SP, Gerstenblith G, Oetjen WJ, Powe NR (2000) Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 101:2239
Tiefenbrunn AJ, Chandra NC, French WJ et al. (1998) Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 31:1240–1245
Trappe HJ, Brugada P, Lezaun R, Wellens HJ (1989) The significance of ventricular tachycardia morphology for prognosis and follow-up. Z Kardiol 78:633–639
Tunstall-Pedoe H, Kuulasmaa K, Mahonen M et al. (1999) Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 353:1547–1557
Urban P, Stauffer JC, Bleed D et al. (1999) A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J 20:1030–1038
Virmani R, Burke AP, Farb A (1998) Plaque morphology in sudden coronary death. Cardiologia 43:267–271
Wallentin L, Goldstein P, Armstrong PW et al. (2003) Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting (ASSENT 3 Plus). Circulation 108:135–142
Weaver WD (1995) Time to thrombolytic treatment: factors affecting delay and their influence on outcome. J Am Coll Cardiol 25:3S–9S
Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, Eisenberg M (1993) Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 270:1211–1216
Werf F van de, Ardissino D, Betriu A et al. (2003) Management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force of the ESC. Eur Heart J 24:28–66
White HD (2000) Thrombolytic therapy in the elderly. Lancet 356:228–230
Widimsky P, Budesinsky T, Vorac D et al. „PRAGUE“ Study Group Investigators (2003) Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial — PRAGUE-2. Eur Heart J 24:94–104
Woods KL, Fletcher S, Roffe C, Haider Y (1992) Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 339:1553–1558
Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335–371
Yusuf S, MacMahon S, Collins R, Peto R (1988) Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1:1088–1092
Yusuf S, Held P, Furberg C (1991) Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 67:1295–1297
Yusuf S, Lessem J, Jha O et al. (1993) Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated controlled trials. J Hypertens Suppl 11:61–73
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 345:494–502
Zijlstra F, Hoorntje JC, Boer MJ de et al. (1999) Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 341:1413–1419
Zipes DP, Wellens HJ (1998) Sudden cardiac death. Circulation 98:2334–2351
Interessenkonflikt:
Der korrespondierende Autor weist auf eine Verbindung mit folgender Firma/Firmen hin: Prof. Böttiger leitet die int. TROICA-Studie, die von der Fa. Boehringer-Ingelheim unterstützt wird.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schiff, JH., Arntz, H.R. & Böttiger, B.W. Das akute Koronarsyndrom in der Prähospitalphase. Anaesthesist 54, 957–974 (2005). https://doi.org/10.1007/s00101-005-0897-z
Issue Date:
DOI: https://doi.org/10.1007/s00101-005-0897-z